Rapid optimization and prototyping for therapeutic antibody-like molecules.
Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
Rapid optimization and prototyping for therapeutic antibody-like molecules.
Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.
Targeting HER3 for cancer treatment: a new horizon for an old target.
Thirty Years of HER3: From Basic Biology to Therapeutic Interventions.
Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia.
Mechanisms of resistance to ErbB-targeted cancer therapeutics.
Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Therapeutic Targeting of the IGF Axis.
Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas.
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
The insulin and insulin-like growth factor receptor family in neoplasia: an update.
ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers.
- Read Time: 1 min